Immune thrombocytopenia: No longer 'idiopathic'

5. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among
adult patients with primary immune thrombocytopenia in the United
Kingdom General Practice Research Database. Haematologica 2010;
95:1167–1175.
6. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration
of a thrombocytopenic factor in the blood of patients with thrombocytopenic
purpura. J Lab Clin Med 1951; 38:1–10.
7. Luiken GA, McMillan R, Lightsey AL, et al. Platelet-associated IgG in immune
thrombocytopenic purpura. Blood 1977; 50:317–325.
8. Hirschman RJ, Schulman NR. Utilization of the platelet release reaction
to measure ITP factor and platelet antibodies. Trans Assoc Am Physicians
1972; 85:325–334.
9. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J
Med 2002; 346:995–1008.
10. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet
1997; 349:1531–1536.
11. Psaila B, Bussel JB. Fc receptors in immune thrombocytopenias: a target for
immunomodulation? J Clin Invest 2008; 118:2677–2681.
12. Aster RH. Molecular mimicry and immune thrombocytopenia (comment).
Blood 2009; 113:3887–3888.
13. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter
pylori CagA protein may be involved in the pathogenesis of H. pylori-associated
chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004;
124:91–96.
14. Nardi MA, Liu LX, Karpatkin S. GPIIIa-(49-66) is a major pathophysiologically
relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related
immunologic thrombocytopenia. Proc Natl Acad Sci U S A 1997;
94:7589–7594.
15. Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular
mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis Crelated
immunologic thrombocytopenia. Blood 2009; 113:4086–4093.
16. Pivetti S, Novarino A, Merico F, et al. High prevalence of autoimmune
phenomena in hepatitis C virus antibody positive patients with lymphoproliferative
and connective tissue disorders. Br J Haematol 1996; 95:204–211.
17. Pawlotsky JM, Bouvier M, Fromont P, et al. Hepatitis C virus infection and
autoimmune thrombocytopenic purpura. J Hepatol 1995; 23:635–639.
18. Sakuraya M, Murakami H, Uchiumi H, et al. Steroid-refractory chronic
idiopathic thrombocytopenic purpura associated with hepatitis C virus
infection. Eur J Haematol 2002; 68:49–53.
19. García-Suárez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-
Mon M. HCV-associated thrombocytopenia: clinical characteristics and
platelet response after recombinant alpha2b-interferon therapy. Br J
Haematol 2000; 110:98–103.
20. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia:
clinical and laboratory characteristics compared with chronic
immune thrombocytopenic purpura. Br J Haematol 2005; 129:818–824.
21. Harker LA. Thrombokinetics in idiopathic thrombocytopenic purpura. Br J
Haematol 1970; 19:95–104.
22. Branehög I, Kutti J, Weinfeld A. Platelet survival and platelet production
in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 1974;
27:127–143.
23. Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with
idiopathic thrombocytopenic purpura and moderate thrombocytopenia.
Blood 1985; 65:584–588.
24. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter
SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic
purpura. Evidence of both impaired platelet production and
increased platelet clearance. J Clin Invest 1987; 80:33–40.
25. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro
megakaryocyte production by antiplatelet autoantibodies from adult
patients with chronic ITP. Blood 2004; 103:1364–1369.
26. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and
mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;
97:2549–2554.
27. Provan D, Stasi R, Newland AC, et al. International consensus report on
the investigation and management of primary immune thrombocytopenia.
Blood 2010; 115:168–186.
28. British Committee for Standards in Haematology General Haematology
Task Force. Guidelines for the investigation and management of idiopathic
McCRAE
thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol
2003; 120:574–596.
29. Mazzucconi MG, Fazi P, Bernasconi S, et al; Gruppo Italiano Malattie Ematoligiche
dell’Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy
with high-dose dexamethasone (HD-DXM) in previously untreated
patients affected by idiopathic thrombocytopenic purpura: a GIMEMA
experience. Blood 2007; 109:1401–1407.
30. Gaines AR. Disseminated intravascular coagulation associated with acute
hemoglobinemia or hemoglobinuria following RH9O)(D) immune globulin
intravenous administration for immune thrombocytopenic purpura. Blood
2005; 106:1532–1537.
31. George JN, Kojouri K, Perdue JJ, Vesely SK. Management of patients with
chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol
2000; 37:290–298.
32. Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Long term
follow-up after splenectomy performed for immune thrombocytopenic
purpura (ITP). Am J Hematol 2003; 72:94–98.
33. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients
with idiopathic thrombocytopenic purpura: a systematic review to assess
long-term platelet count responses, prediction of response, and surgical
complications. Blood 2004; 104:2623–2634.
34. Stasi R, Provan D. Management of immune thrombocytopenic purpura in
adults. Mayo Clin Proc 2004; 79:504–522.
35. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed
idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal
antibody rituximab: a pilot study. Eur J Haematol 2002; 69:95–100.
36. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to
rituximab treatment in adults with chronic idiopathic thrombocytopenic
purpura (letter). Blood 2002; 99:3872–3873.
37. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and
safetyof B-cell depletion with anti-CD20 monocloncal antibody in adults
with chronic immune thrombocytopenic purpura. Br J Haematol 2004;
125:232–239.
38. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune
cytoopenia in adults: idiopathic thrombocytopenic purpura, autoimmune
hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78:1340–
1346.
39. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB.
Long term follow-up of patients with immune thrombocytopenic purpura
(ITP) whose initial response to rituximab lasted a minimum of 1 year
(abstract). Blood (ASH Annual Meeting Abstracts): 2006; 108:Abstract 479.
40. Mukai HY, Kojima H, Todokoro K, et al. Serum thrombopoietin (TPO) levels
in patients with amegakaryocytic thrombocytopenia are much higher than
those with immune thrombocytopenic purpura. Thromb Haemost 1996;
76:675–678.
41. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating
protein, for chronic ITP. N Engl J Med 2006; 355:1672–1681. (Published
correction in N Engl J Med 2006; 355:2054.)
42. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients
with chronic immune thrombocytopenic purpura: a double-blind randomised
controlled trial. Lancet 2008; 371:395-403.
43. Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding
and thrombotic events during long-term use of romiplostim in patients
with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010;
8:1372–1382.
44. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of
chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase
3 study. Lancet 2010 Aug 23 (Epub ahead of print).
45. Saleh MN, Bussel JB, Cheng G, et al. Long-term treatment of chronic immune
thrombocytopenic purpura with oral eltrombopag. Abstract #682
presented at the 51st American Society of Hematology Annual Meeting
and Exposition, New Orleans, LA, December 5–8, 2009; http://ash.confex.
com/ash/2009/webprogram/Paper24081.html. Accessed April 26, 2011.
46. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation
of bone marrow reticulin formation in chronic immune thrombocytopenia
patients treated with romiplostim. Blood 2009; 114:3748–3756.
ADDRESS: Keith McCrae, MD, Department of Hematologic Oncology and
Blood Disorders, R4-018, Cleveland Clinic, 9500 Euclid Avenue, Cleveland,
OH 44195; e-mail mccraek@ccf.org.
CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 78 • NUMBER 6 JUNE 2011 373